INTERVIEW: SkinBioTherapeutics Plc Contract extension accelerates development work

SkinBioTherapeutics Plc (LON:SBTX) CEO Dr Catherine O’Neill talks to DirectorsTalk about the extension of a contract with the University of Manchester. Catherine explains the purpose and audience of SkinBiotix, how the company will benefit from the extension of the research contract, the importance of being labelled ‘dermatologically tested’ and what investors should be looking out for in terms of news flow.

SkinBioTherapeutics Plc is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company’s platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The company received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix Health Plc (LON:OPTI).

Find more news, interviews, share price & company profile here for:

    You can also listen to our interviews on: 

    Share this interview

    Twitter
    LinkedIn
    Facebook
    Email
    WhatsApp
    SkinBioTherapeutics plc
    INTERVIEW: SkinBioTherapeutics Plc Contract extension accelerates development work

    Other Interviews

    More News

    Ask your questions

    Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

    I have questions